FLORENCE, Italy — During the 2025 European Congress of Internal Medicine, held from March 5 to 8, the scientific program featured a special session in collaboration with the European Society of ...

Hypertension — or high blood pressure — affects about 120 million adults in the U.S. and can lead to heart disease, stroke and chronic kidney disease. There is also a higher prevalence of hypertension ...

High blood pressure often lurks without symptoms, earning its reputation as the “silent killer.” With nearly half of American adults affected by this condition, understanding the different stages of ...

A groundbreaking development in hypertension treatment has emerged from the University of South Wales, offering new hope for the 1.28 billion adults worldwide affected by high blood pressure. This ...

Mineralys Therapeutics announced the positive results of its Launch-HTN trial, the largest study of an aldosterone synthase inhibitor for patients with uncontrolled or treatment-resistant hypertension ...

Vivek Bhalla, MD, Stanford, calls for greater awareness and implementation of existing screening guidelines to help identify patients who may benefit from more targeted, disease-specific interventions ...

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The World Health Organization estimates that there are at least 270 million people living with hypertension in China — a fraction of whom are being adequately treated, if at all. Part of the problem ...

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or ...

To derive blood pressure, the device measures the time-of-flight between ultrasound echoes reflected from the anterior and ...